Novacyt S.A. (ALNOV.PA)
- Previous Close
0.8400 - Open
0.8280 - Bid --
- Ask --
- Day's Range
0.7960 - 0.8280 - 52 Week Range
0.4200 - 0.9950 - Volume
131,739 - Avg. Volume
179,176 - Market Cap (intraday)
56.218M - Beta (5Y Monthly) -1.71
- PE Ratio (TTM)
-- - EPS (TTM)
-0.4200 - Earnings Date Apr 25, 2024 - Apr 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.12
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
www.novacyt.comRelated News
Performance Overview: ALNOV.PA
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALNOV.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALNOV.PA
Valuation Measures
Market Cap
56.22M
Enterprise Value
-38.52M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.13
Price/Book (mrq)
0.45
Enterprise Value/Revenue
-4.89
Enterprise Value/EBITDA
2.59
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-5.88%
Return on Equity (ttm)
-21.08%
Revenue (ttm)
7.87M
Net Income Avi to Common (ttm)
-25.3M
Diluted EPS (ttm)
-0.4200
Balance Sheet and Cash Flow
Total Cash (mrq)
81.74M
Total Debt/Equity (mrq)
0.36%
Levered Free Cash Flow (ttm)
-9.66M
Research Analysis: ALNOV.PA
Company Insights: ALNOV.PA
ALNOV.PA does not have Company Insights